World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
35405
World Ranking
10013
National Ranking
5153

Overview

Tapan M. Kadia is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on the field of Medicine, with a significant concentration in Hematology, Genetics, Molecular Biology, Public Health, Environmental and Occupational Health, and Oncology. Their work encompasses a broad range of topics related to leukemia and other hematological malignancies.

Key areas of study for Kadia include:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Acute Lymphoblastic Leukemia research
  • Chronic Lymphocytic Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Histone Deacetylase Inhibitors Research
  • Protein Degradation and Inhibitors

Their recent publications reflect contributions to understanding acute myeloid leukemia and related treatments, including:

  • "Acute myeloid leukemia: current progress and future directions," 2021, Blood Cancer Journal
  • "Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges," 2020, Cancer Discovery
  • "Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia," 2021, Journal of Clinical Oncology
  • "10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial," 2020, The Lancet Haematology
  • "De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017," 2021, Cancer

Frequent co-authors contributing to their body of work include:

  • Farhad Ravandi
  • Courtney D. DiNardo
  • Hagop M. Kantarjian
  • Nicholas J. Short
  • Guillermo Garcia-Manero

Tapan M. Kadia's publications are often found in prominent hematology and oncology journals. Notable publication venues with the highest number of their contributions include:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • American Journal of Hematology
  • HemaSphere

Best Publications

  • Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

    Marina Konopleva;Daniel A. Pollyea;Jalaja Potluri;Brenda Chyla

  • Acute myeloid leukemia: current progress and future directions.

    Hagop Kantarjian;Tapan Kadia;Courtney DiNardo;Naval Daver

  • Ibrutinib and venetoclax for first-line treatment of CLL

    Nitin Jain;Michael Keating;Philip Thompson;Alessandra Ferrajoli

  • Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.

    Naval Daver;Guillermo Garcia-Manero;Sreyashi Basu;Prajwal C Boddu

  • Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

    Courtney D. DiNardo;Caitlin R. Rausch;Christopher Benton;Tapan Kadia

  • Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

    Hagop M. Kantarjian;Susan OBrien;Elias Joseph Jabbour;Guillermo Garcia-Manero

  • Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.

    Hagop M. Kantarjian;Farhad Ravandi;Susan OBrien;Jorge Cortes

  • Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

    Farhad Ravandi;Mona Lisa Alattar;Michael R. Grunwald;Michelle A. Rudek

  • Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.

    Nitin Jain;Audrey V. Lamb;Susan O’Brien;Farhad Ravandi

  • Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase

    Jorge E. Cortes;Dan Jones;Susan O'Brien;Elias Jabbour

  • Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

    Courtney D. DiNardo;Farhad Ravandi;Sam Agresta;Marina Konopleva

  • Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: A single-centre, phase 2 study

    Elias Jabbour;Hagop Kantarjian;Farhad Ravandi;Deborah Thomas

  • Long-term outcome of acute promyelocytic leukemia treated with all- trans-retinoic acid, arsenic trioxide, and gemtuzumab

    Yasmin Abaza;Hagop M. Kantarjian;Guillermo Garcia-Manero;Elihu Estey

  • Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.

    Nicholas J. Short;Marina Konopleva;Tapan M. Kadia;Gautam Borthakur

  • 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.

    Courtney D DiNardo;Abhishek Maiti;Caitlin R Rausch;Naveen Pemmaraju

  • Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

    Naval Daver;Deborah Thomas;Farhad Ravandi;Jorge Cortes

  • Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.

    Hagop Kantarjian;Farhad Ravandi;Nicholas J Short;Xuelin Huang

  • Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

    Srdan Verstovsek;Hagop M. Kantarjian;Zeev Estrov;Jorge E. Cortes

  • TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes.

    Tapan M. Kadia;DM Preetesh Jain Md;Farhad Ravandi;Guillermo Garcia-Manero

  • Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

    Courtney D. DiNardo;Curtis A. Lachowiez;Koichi Takahashi;Sanam Loghavi

Frequent Co-Authors

Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Naval Daver
Naval Daver The University of Texas MD Anderson Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center
Keyur P. Patel
Keyur P. Patel The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Alessandra Ferrajoli
Alessandra Ferrajoli The University of Texas MD Anderson Cancer Center
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Kapil N. Bhalla
Kapil N. Bhalla The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in medicine doesn’t always mean pursuing an MD. Today, a range of accredited online degrees empower students to enter rewarding healthcare fields with greater flexibility and often at a lower cost.

Those interested in mental health can earn advanced practice credentials through psych np programs, which prepare you for roles as Psychiatric Nurse Practitioners. Another popular route is healthcare management. If you’re aiming for operational or leadership positions, a bachelors in health administration provides a strong foundation in organizational strategy, public health, and policy.

Professionals seeking to advance may choose a master’s degree. The cheapest mha programs online healthcare offer affordability as well as specialization in critical administrative skills. For clinical leadership and the highest level of nursing practice, the best dnp programs online are designed to foster innovation and evidence-based care.

These online pathways can open doors to upward mobility and help address the nation’s evolving healthcare needs, all while accommodating busy student schedules.

Best Scientists Citing Tapan M. Kadia

Trending Scientists

Recently Published Articles